Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | LPL | P06858 | 1/20 | 0.37 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.37 |
| ▸ | TUBB4A | P04350 | 3/20 | 0.36 |
| ▸ | TUBB | P07437 | 3/20 | 0.36 |
| ▸ | TUBA3C | P0DPH7 | 3/20 | 0.36 |
| ▸ | TUBA1B | P68363 | 3/20 | 0.36 |
| ▸ | TUBA4A | P68366 | 3/20 | 0.36 |
| ▸ | TUBB4B | P68371 | 3/20 | 0.36 |
| ▸ | TUBB3 | Q13509 | 3/20 | 0.36 |
| ▸ | TUBB2A | Q13885 | 3/20 | 0.36 |
| ▸ | TUBB8 | Q3ZCM7 | 3/20 | 0.36 |
| ▸ | TUBA3E | Q6PEY2 | 3/20 | 0.36 |
| ▸ | TUBA1A | Q71U36 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3912855 | 0.89 | CYP3A4 (0.39) | ENPP2CA2CA1RXFP1MEN1 | |
| SCHEMBL28825759 | 0.86 | ENPP2 (0.41) | ENPP2CA2CA1RXFP1MEN1 | |
| SCHEMBL13108507 | 0.81 | ENPP2 (0.33) | ENPP2CA2CA1RXFP1MEN1 | |
| SCHEMBL24433 | 0.81 | CYP3A4 (0.56) | ENPP2CA2CA1MEN1KMT2A | |
| SCHEMBL3327791 | 0.81 | CA1 (0.48) | ENPP2CA2CA1KMT2ACYP3A4 | |
| SCHEMBL4109993 | 0.79 | ENPP2 (0.41) | ENPP2CA2CA1MEN1KMT2A | |
| SCHEMBL5628199 | 0.79 | ENPP2 (0.41) | ENPP2CA2CA1CYP3A4TUBB4A | |
| SCHEMBL10132747 | 0.79 | ACHE (0.45) | ENPP2CA2CA1CYP3A4TUBB4A | |
| SCHEMBL10165239 | 0.77 | ENPP2 (0.36) | ENPP2CA2CA1LPLLIPG | |
| SCHEMBL16071684 | 0.76 | CYP3A4 (0.42) | ENPP2CA2CA1RXFP1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663936-B1 | BIARYLOXYMETHYLARENE-CARBOXYLIC ACIDS | HOFFMANN LA ROCHE (CH) | 2008-01-09 | — | — | EP | disclosed |
| US-7196101-B2 | Bis(5-aryl-2-pyridyl) compound having excellent immunoglobulin (IgE) antibody production inhibiting activity, useful for the prevention or treatment of allergic immune diseases | KOWA CO., LTD (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| US-6706703-B2 | BIS(5-ARYL-2-PYRIDYL) COMPOUND HAVING EXCELLENT IMMUNOGLOBULIN (IGE) ANTIBODY PRODUCTION INHIBITING ACTIVITY, USEFUL FOR THE PREVENTION OR TREATMENT OF ALLERGIC IMMUNE DISEASES | KOWA CO., LTD. (JP) | 2004-03-16 | — | — | US | disclosed |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | KOWA CO., LTD. (JP) | 2003-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050101634-A1 | Bis(5-aeyl-2-pyridyl) derivatives | H1-0, BRD4, PAH | ENPP2 1436/4885CA2 422/4885CA1 2904/4885 |
| US-20030027814-A1 | Bis(5-aryl-2-pyridyl) derivatives | AHR, PAH, H1-0 | ENPP2 2995/4885CA2 2662/4885CA1 4598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.